Evidence map›Paper›PMID 27778143›Full record

ReviewCurrent hematologic malignancy reports2016

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Bradley M Haverkos, Zenggang Pan, Alejandro A Gru, Aharon G Freud, Rachel Rabinovitch, Meng Xu-Welliver, Brad Otto, Carlos Barrionuevo, Robert A Baiocchi, Rosemary Rochford and 1 more

Open access · greenAbstract readReview
In one paragraph

Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 3 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Estimating the global burden of Epstein-Barr virus-related cancers.Journal of cancer research and clinical oncology · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Lymphomatoid papulosis: a practical review for pathologists.Journal of pathology and translational medicine · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Bradley M HaverkosDivision of Hematology, University of Colorado, 1665 Aurora Ct., Mail Stop F754, Aurora, CO, 80045, USA. bradley.haverkos@ucdenver.edu.
Zenggang PanDepartment of Pathology, University of Colorado, Aurora, CO, USA.
Alejandro A GruDepartment of Pathology and Dermatology, University of Virginia, Charlottesville, VA, USA.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Rachel RabinovitchDepartment of Radiology, University of Colorado, Aurora, CO, USA.
Meng Xu-WelliverDepartment of Radiation Oncology, The Ohio State University, Columbus, OH, USA.
Brad OttoDepartment of Otolaryngology, Ohio State University, Columbus, OH, USA.
Carlos BarrionuevoDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasticas (I.N.E.N.), Lima, Peru.
Robert A BaiocchiDivision of Hematology and Comprehensive Cancer Center, Ohio State University, 320 West 10th Avenue, Columbus, OH, 43210, USA.
Rosemary RochfordDepartment of Immunology and Microbiology, University of Colorado, Aurora, CO, USA.
Pierluigi PorcuDivision of Hematology and Comprehensive Cancer Center, Ohio State University, 320 West 10th Avenue, Columbus, OH, 43210, USA.
The Ohio State University · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USInstituto Nacional de Enfermedades Neoplásicas · PEUniversity of Virginia · US

Funding

NCI NIH HHS L30 CA189070
6 · The paper itself

Abstract

purpose of reviewExtranodal NK/T cell lymphoma, nasal type (ENKTL-NT) is an aggressive extranodal non-Hodgkin lymphoma most commonly occurring in East Asia and Latin America but with increasing incidence in the United States. Data on epidemiology, disease presentation, and outcome for European and North American ("Western") cases are very limited. We review published landmark clinical studies on ENKTL-NT in the West and report in detail recent data, including our institutional experience. RECENT

findingsWe highlight key observations in its epidemiology, natural history, and trends in clinical management. In the USA, ENKTL-NT is more common among Asian Pacific Islanders (API) and Hispanics compared to non-Hispanic whites. Published studies indicate less heterogeneity in clinical presentation in Western ENKTL-NT compared to Asian patients. While there is variation in age at diagnosis, presence of antecedent lymphoproliferative disorders, and outcomes among racial/ethnic groups, the universal association of ENKTL-NT with EBV and the poor response of this neoplasm to anthracycline-based therapy is consistent across all geographic areas. Data on epidemiology, disease presentation, and clinical outcomes in mature T cell and NK cell (T/NK cell) neoplasms, including ENKTL-NT, in Europe and North America are very limited. As the classification and diagnostic characterization of the currently recognized T/NK cell lymphoma disease entities continue to evolve, gaps and inconsistencies in data reporting across different studies are being recognized. Despite these limitations, several studies from the USA suggest that the incidence of ENKTL-NT is higher in Asian Pacific Islanders (API) and non-white Hispanics and that outcomes may be worse in non-whites. However, the universal association of ENKTL-NT with Epstein-Barr virus (EBV) across all ethnic groups suggests a common pathogenesis. Given the overlap between the entities included in the category of T/NK cell neoplasms, there is a need to further define biological and clinical differences that may affect diagnosis, treatment, and outcome.

Indexed as

Antineoplastic AgentsAsparaginaseBiomarkersDNA, ViralEuropeHerpesvirus 4, HumanHumansLymphoma, Extranodal NK-T-CellNorth AmericaAntineoplastic AgentsAsparaginaseBiomarkersDNA, ViralENKTLEpstein–Barr virusEuropeExtranodal NK/T cell lymphomaUnited KingdomUnited States

Identifiers

PMID27778143
PMCPMC5199232
OpenAlexW2537909502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.